Collagen Dressings Market Trends

Growth Drivers

• Accelerated R&D investments: The clinical evidence offered by numerous studies led to improved investments in the market, thereby launching more of such effective formulations. For instance, in 2024, NIH invested USD 97 million with a focus on antimicrobial-infused and 3D-printed dressings. Simultaneously, in Europe EU Horizon allocated €62.3 million for marine collagen commercialization, targeting a 42% cost reduction by the end of 2027.
• Well-planned collaborations: The commendable strategies implemented by the key players also propel growth in the collagen dressings market. For instance, in 2024, Smith & Nephew announced a partnership with Apollo Hospitals based in India that resulted in a 16% increase in adoption in South Asia. In addition, Convatec received the U.S. FDA approval for Collagen+Silver dressing in 2025 and captured 9.3% market share in the first quarter of 2025, hence creating a prolific market opportunity.

Historical Patient Growth (2010-2020): Foundation for Future Market Expansion

The last decade, from 2010 to 2020, has been a transitional period for the collagen dressings market, attributed to the expanding wound prevalence, aging demographics, and improved wound care awareness. This has created a strong foundation for the current market trends, with North America and Europe grabbing the maximum revenue share, whereas Asia-Pacific emerged as the fastest-growing region. Therefore, the expanded patient base encourages the players to establish domestic production hubs and collaborations with insurers to improve reimbursement access.

Below are the 2010-2020 patient growth data for key markets:

Manufacturer Strategies Driving Market Expansion

Prominent manufacturers involved in the market are willing to secure their market positions with the implementation of three crucial strategies, including product innovation, such as antimicrobial, hybrid dressings, partnerships with insurers/hospitals, and domestic production to reduce costs. Furthermore, the adoption of these moves reflects a broader trend as 72% of wound care products covered under Medicare currently include advanced collagen variants, states the CMS data, whereas in Europe EU’s MDR 2027 is anticipated to phase out 32% of legacy dressings, creating a €320 million replacement market.

Revenue Growth Opportunities for Manufacturers (2023-2025)

Challenge

• Limited awareness & standardization concerns: This remains a major bottleneck in the market to capture the required consumer base. In this context, the CDC data found that 62% of clinicians in Southeast Asia still rely on traditional gauze dressings for chronic wounds. Whereas audits conducted by PAHO revealed that approximately 26% of collagen dressings in Brazil and Mexico fail to meet ISO 13485 standards owing to the presence of sterilization and packing inefficiencies. Therefore, the presence of these factors is hampering market growth across certain nations, creating significant healthcare disparities.